Publicaciones en colaboración con investigadores/as de Hospital Universitario Doctor Peset (24)

2024

  1. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

    Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461

2023

  1. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  2. No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

    Disease markers, Vol. 2022, pp. 3132941

  3. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

    Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295

  4. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

    Cancers, Vol. 14, Núm. 7

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014

  2. Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients

    Leukemia and Lymphoma, Vol. 62, Núm. 11, pp. 2727-2736

  3. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

    Leukemia, Vol. 35, Núm. 6, pp. 1571-1585

  4. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  5. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

    Transplantation and Cellular Therapy, Vol. 27, Núm. 4, pp. 311.e1-311.e10

  6. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

  7. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

    Scientific Reports, Vol. 11, Núm. 1

  8. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2017

  1. Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin

    Annals of Hematology, Vol. 96, Núm. 7, pp. 1077-1084

2016

  1. A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia

    British Journal of Haematology, Vol. 174, Núm. 5, pp. 700-710

2015

  1. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

    Leukemia and Lymphoma, Vol. 56, Núm. 2, pp. 415-419

  2. Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia

    Annals of Hematology, Vol. 94, Núm. 8

2013

  1. Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

    Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74